พรีเวนทรา 9

• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 6 L1 PROTIEN30 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 11 L1 PROTIEN40 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 16 L1 PROTIEN60 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 18 L1 PROTIEN40 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 31 L1 PROTIEN20 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 33 L1 PROTIEN20 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 45 L1 PROTIEN20 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 52 L1 PROTIEN20 microgramต่อ 0.5 milliliter
• RECOMBINANT HUMAN PAPILLOMAVIRUS VIRUS TYPE 58 L1 PROTIEN20 microgramต่อ 0.5 milliliter

ประเภทควบคุม

ยาควบคุมพิเศษ

ข้อบ่งใช้

Preventra 9 is indicated for women aged 9 – 45 years for preventing the following diseases caused by human papillomavirus (HPV) types contained in the vaccine. The following diseases caused by HPV types 16 and 18: - Cervical cancer - Cervical intraepithelial neoplasia Grade 2 or 3 (CIN2/3) and adenocarcinoma in-situ (AIS) - Cervical intraepithelial neoplasia Grade 1 (CIN1) Clinical study data for persistent infections caused by HPV types 16, 18, 31, 33, 45, 52 and 58 has been obtained. The protective efficacy study on CIN, AIS and cervical cancer caused by HPV types 31, 33, 45, 52 and 58, as well as genital warts caused by HPV types 6 and 11, is ongoing.

รหัส ATC

J07BM03 (papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58))

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ